Fig. 2: Volasertib-induced PD-L1 upregulation is dependent on MAPK.
From: Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment
a PD-L1 surface expression of NSCLC cells (H460) treated with vehicle control (0.1% DMSO in PBS), SCH772984 (ERK1/2 small molecule inhibitor, 1 μM), volasertib (100 nM), or SCH772984 (SCH; 1 μM) + volasertib (vol; 100 nM) – (left) representative histograms, (right) MFI quantification. Data presented as mean MFI (median fluorescent Intensity) from biological duplicates, 10,000 events collected per sample. b PD-L1 surface expression of H460 cells treated with vehicle control (0.1% DMSO in PBS), SC75741 (NF-kB inhibitor, 1 μM), volasertib (100 nM), or SC75741 (SC75; 1 μM) + volasertib (vol; 100 nM) – (left) representative histograms, (right) MFI quantification. Data presented as mean MFI from biological duplicates, 10,000 events collected per sample. Source data are provided as a Source Data file.
